STRATEGIC NEWS WATCH — September 4, 2026
|
Ionis’s Zanvastro (zilganersen) becomes the first-ever approved therapy for Alexander disease — a rare, typically fatal neurological disorder caused by GFAP mutations that had no disease-modifying treatment until today — clearing the FDA on Priority Review and extending the company’s antisense platform into a corner of CNS disease that other modalities have failed to reach. Today’s top developments:
|
What to Watch
- Zanvastro’s label and price — Efficacy numbers, the approval pathway, and pricing were all absent from launch coverage. The FDA label will settle trial size, endpoints, and whether this is a standard or accelerated approval — the details that determine how far the antisense read-through actually extends.
- Ionis’s Angelman exposure — Ultragenyx’s apazunersen failed Phase 3 in Angelman this week on a mechanism Ionis is also pursuing. The tell will be whether Ionis reaffirms or trims guidance on its own Angelman antisense candidate now that the first pivotal read-out in the indication is negative.
- The VESALIUS-CV hazard ratio — Amgen has put out 20% all-cause mortality and 36% MI reduction across two announcements with no hazard ratio or confidence interval. The Circulation paper and the 24% LDL-goal-attainment figure are the only real tests of whether “inflection” describes prescriber behaviour or just marketing.
- The China-origin GLP-1 licensing pattern — Menarini’s up-to-$771M deal for Gan & Lee’s bofanglutide is the third China in-licensing move in two weeks, after Roche-Simcere and GSK-HUTCHMED. The signal to track is whether European mid-caps keep buying ex-China obesity rights at modest upfronts as their only realistic route against Novo and Lilly.
- The HRT demand-and-supply lag — The FDA is rallying manufacturers to fix an estradiol-patch shortage it links to the removal of HRT boxed warnings. Should that link hold, it becomes a clean case study in how fast safety-label liberalisation moves demand ahead of supply — a dynamic likely to recur with any future boxed-warning removal.
This brief highlights the edition’s top stories. Read the full September 4, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.